Relative cerebral blood volume of tumor habitats can differentiate presurgical IDH-wildtype glioblastoma from IDH-mutant astrocytoma grade 4.
María del Mar Álvarez-Torres1, Elies Fuster-Garcia1,2, Carmen Balaña3, Josep Puig4, Gaspar Reynes5, Kyrre Eeg Emblem2, Enrique Mollà-Olmos6, Jose Pineda7,8, and Juan M García-Gómez1
1Biomedical Data Science Laboratory. ITACA, Universitat Politècnica de València, Valencia, Spain, 2Oslo University Hospital, Oslo, Norway, 3Institut Catala Oncologia Badalona, Barcelona, Spain, 4Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Girona, Spain, 5Instituto de Investigación Sanitaria La Fe, Valencia, Spain, 6Hospital de la Ribera, Alzira, Valencia, Spain, 7Hospital Clinic de Barcelona, Barcelona, Spain, 8void.space Lab, Facultat de Medicina, Universitat de Vic, Vic, Spain
IDH-wildtype glioblastoma and IDH-mutant astrocytoma are classified as different gliomas according to WHO 2021. IDH mutations are key at clinical level, since they are associated with patient prognosis and seem to be critical for treatment selection. Despite these evidences, current protocols do not include the full sequencing for all tumors. In this sense, non-invasive and automatically calculated MRI-based biomarkers can be helpful for the clinical practice.
Our results show that perfusion markers obtained in an automated, repeatable, and non-invasive manner may be candidates for being surrogate predictive markers of IDH mutation status in astrocytomas grade 4.
This abstract and the presentation materials are available to members only;
a login is required.